Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926444 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
A Phase 2 study of Cancer and Pain, sponsored by gicare Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
- 15
- Study locations
NCT01926444 is a Phase 2 study of Cancer and Pain that has completed, run by gicare Pharma. The registered enrollment target is 308 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT01926444, a Phase 2 study of Cancer and Pain, has completed, sponsored by gicare Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
- 15
- Study locations
Study Summary
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy. It will be evaluated for efficacy and safety in a multi-center, randomized, double-blind, placebo controlled, dose-ranging, proof of concept Phase 2a trial. Up to 240 patients will receive one of 3 doses of GIC-1001 or its matching placebo. A pharmacokinetic evaluation will be carried out on a subset of patients (N: 24).
Conditions Studied
Interventions
- DRUG GIC-1001
Study Locations (15)
California
- Anaheim Clinical Trials - Anaheim
- Precision Research Institute - Chula Vista
- Precision Research Institute - San Diego
Florida
- Avail Clinical Research LLC - DeLand
- The Center for GI Disorders - Hollywood
Quebec
- Clinique 1037 - Montreal
- Spécialistes MD Specialists - Montreal
Arizona
- Mayo Clinic - Scottsdale
Maryland
- Mid-Atlantic Medical Research Centers - Hollywood
Minnesota
- Mayo Clinic Rochester - Rochester
New Jersey
- PharmaTrials - Hillsborough
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01926444
The ClinicalTrials.gov registry entry for NCT01926444 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (91% lower). The listed sponsor is gicare Pharma, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which GIC-1001 is the first listed.
NCT01926444 reports 15 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Quebec.
Frequently Asked Questions
What is clinical trial NCT01926444 about?
NCT01926444 is a clinical study titled "A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy". GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy. It will be evaluated for efficacy and safety in a multi-center, randomized, double-blind, placebo controlled, dose-ranging, proof of concept Phase 2a trial. Up to 24...
What is the current status of trial NCT01926444?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2013-07. Estimated completion is 2014-03.
What conditions does trial NCT01926444 study?
This clinical trial studies the following conditions: Cancer, Pain, Colonic Diseases.
What interventions are being tested in trial NCT01926444?
The interventions under investigation include: GIC-1001 (DRUG).
Who is sponsoring clinical trial NCT01926444?
This trial is sponsored by gicare Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01926444 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.